Hyperfine (HYPR) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Hyperfine (HYPR) has outperformed Stereotaxis (STXS) over the past year, losing 53.0% versus a loss of 67.1%. Over five years, STXS leads with a -81.3% price change compared with -90.6% for HYPR. Stereotaxis is the larger company by market cap ($111.2 million vs $98.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPR | STXS |
|---|---|---|
| Share price | $0.9307 | $1.11 |
| Market cap | $98.70M | $111.22M |
| 1-day change | -1.00% | 0.00% |
| YTD return | -4.93% | -51.74% |
| 1-year return | -52.99% | -67.06% |
| 5-year return | -90.64% | -81.28% |
| EPS (TTM) | $-0.37 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.22 | $3.42 |
| 52-week low | $0.754 | $1.09 |
| Distance from 52-week high | -58.08% | -67.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +118.12% | +170.27% |
| Average volume | 765.15K | 808.41K |
| Shares outstanding | 90.99M | 100.20M |
| Employees | 102 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HYPR has outperformed STXS by 14.1 percentage points over the past year.
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
HYPR vs STXS FAQ
Which is bigger, Hyperfine or Stereotaxis?
Stereotaxis (STXS) is larger, with a market capitalization of $111.22M compared with $98.70M for Hyperfine (HYPR).
Which stock has performed better over the past year, HYPR or STXS?
HYPR returned -52.99% over the past 12 months, compared with -67.06% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are Hyperfine and Stereotaxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.